NIKKEI 225
26,911.20 +251.45 (+0.94%) HANG SENG
20,644.28 +41.76 (+0.20%) CRUDE OIL
109.73 -2.67 (-2.38%) GOLD FUTURES
1,816.50 -2.40 (-0.13%) DOW
31,683.25 -971.34 (-2.97%) BTC-GBP
23,524.33 -973.28 (-3.97%)
BRAIN Biotech AG (0RFI.L)
| Previous close | 7.60 |
| Open | 7.60 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 7.60 - 7.60 |
| 52-week range | 7.60 - 7.60 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 137.495M |
| Beta (5Y monthly) | 1.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.33 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
BRAIN Biotech AG: Successful Genome Editing in Mammalian Cells with BRAIN-Metagenome-Cas (BMC), BRAIN-Engineered-Cas (BEC)
DGAP-News: BRAIN Biotech AG / Key word(s): Miscellaneous04.04.2022 / 10:40 The issuer is solely responsible for the content of this announcement.Successful Genome Editing in Mammalian Cells with BRAIN-Metagenome-Cas (BMC), BRAIN-Engineered-Cas (BEC) Major milestone achieved: genome-editing in mammalian cell lines Potential to target very large addressable markets BEC, BMC well suited for different application fieldsZwingenberg, Germany, April, 4th 2022 - BRAIN Biotech AG has achieved a major mil
- EQS Group
BRAIN Biotech AG: Successful Genome Editing Activity in Mammalian Cells with BRAIN-Metagenome-Cas (BMC), BRAIN-Engineered-Cas (BEC)
BRAIN Biotech AG / Key word(s): MiscellaneousBRAIN Biotech AG: Successful Genome Editing Activity in Mammalian Cells with BRAIN-Metagenome-Cas (BMC), BRAIN-Engineered-Cas (BEC) 04-Apr-2022 / 10:31 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Successful Genome Editing Activity in Mammalian Cells with BRAIN-Metagenome-Cas (B
- EQS Group
BRAIN Biotech AG: Resolutions of the Annual General Meeting for the Fiscal Year 2020/2021 of BRAIN Biotech AG
DGAP-News: BRAIN Biotech AG / Key word(s): AGM/EGM09.03.2022 / 16:00 The issuer is solely responsible for the content of this announcement.Resolutions of the Annual General Meeting for the Fiscal Year 2020/2021 of BRAIN Biotech AG Executive Board and Supervisory Board discharged by a large majority Shareholder majority approves capital reserve advance resolutions Positive outlook for the new fiscal yearZwingenberg, Germany, 9 March 2022 - At today's Annual General Meeting of BRAIN Biotech AG, th
